Scholarlink

<p>Glioblastoma multiforme (GBM), the most common malignant primary brain tumor, responds poorly to surgery, radiotherapy, chemotherapy, and immunotherapy, with dismal prognosis and short median survival. There is an urgent need for improved therapies, with supportive and palliative care integral to the multimodal treatment strategy. Traditional Chinese medicine (TCM) exerts antitumor effects via multi-target and multi-pathway mechanisms. Thus, screening and validation of candidate natural small molecules for the therapy and adjuvant therapy of glioblastoma multiforme (GBM) are of great significance. In this study, bioinformatics analysis identified cluster of differentiation 44 (CD44) as a positive correlate of glioblastoma multiforme (GBM). Using cluster of differentiation 44 (CD44) protein structure from the AlphaFold Protein Structure Database, we combined network pharmacology, virtual screening, and molecular docking to pinpoint Schisandrin B (Sch B) as a candidate natural small molecule against glioblastoma multiforme (GBM). In vitro assays verified that Schisandrin B (Sch B) potently inhibited glioblastoma multiforme (GBM) cell proliferation, migration, and invasion. In vivo glioblastoma multiforme (GBM) xenograft models confirmed that Schisandrin B (Sch B) reduced tumor volume, improved mouse survival, and enhanced autonomous activity. Safety evaluations further demonstrated that Schisandrin B (Sch B) had no adverse effects on mouse body weight, autonomous activity, organ index, or tissue morphology. Taken together, Schisandrin B (Sch B) targets cluster of differentiation 44 (CD44) to inhibit glioblastoma multiforme (GBM), and it has relatively good safety performance. This study can provide a research foundation for the therapy and adjuvant therapy of glioblastoma multiforme (GBM).</p> Graphical Abstract <p>CD44 is positively correlated with GBM. Based on the protein structure of CD44, Schisandrin B was obtained through virtual screening. Schisandrin B targets CD44 by binding to the key amino acids T111 and S180 of CD44 to inhibit GBM in vitro and&#xa0;in vivo<i>.</i></p> <p></p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Schisandrin B targets CD44 to inhibit glioblastoma multiforme

  • 期刊论文

  • 发表日期：

    2026年3月2日

查看全文
  • Na Wang,
  • Yuxin Xie,
  • Jialin Chen,
  • Wenpei Chen,
  • Donghao Zhang,
  • Hong Li

摘要

Glioblastoma multiforme (GBM), the most common malignant primary brain tumor, responds poorly to surgery, radiotherapy, chemotherapy, and immunotherapy, with dismal prognosis and short median survival. There is an urgent need for improved therapies, with supportive and palliative care integral to the multimodal treatment strategy. Traditional Chinese medicine (TCM) exerts antitumor effects via multi-target and multi-pathway mechanisms. Thus, screening and validation of candidate natural small molecules for the therapy and adjuvant therapy of glioblastoma multiforme (GBM) are of great significance. In this study, bioinformatics analysis identified cluster of differentiation 44 (CD44) as a positive correlate of glioblastoma multiforme (GBM). Using cluster of differentiation 44 (CD44) protein structure from the AlphaFold Protein Structure Database, we combined network pharmacology, virtual screening, and molecular docking to pinpoint Schisandrin B (Sch B) as a candidate natural small molecule against glioblastoma multiforme (GBM). In vitro assays verified that Schisandrin B (Sch B) potently inhibited glioblastoma multiforme (GBM) cell proliferation, migration, and invasion. In vivo glioblastoma multiforme (GBM) xenograft models confirmed that Schisandrin B (Sch B) reduced tumor volume, improved mouse survival, and enhanced autonomous activity. Safety evaluations further demonstrated that Schisandrin B (Sch B) had no adverse effects on mouse body weight, autonomous activity, organ index, or tissue morphology. Taken together, Schisandrin B (Sch B) targets cluster of differentiation 44 (CD44) to inhibit glioblastoma multiforme (GBM), and it has relatively good safety performance. This study can provide a research foundation for the therapy and adjuvant therapy of glioblastoma multiforme (GBM).

Graphical Abstract

CD44 is positively correlated with GBM. Based on the protein structure of CD44, Schisandrin B was obtained through virtual screening. Schisandrin B targets CD44 by binding to the key amino acids T111 and S180 of CD44 to inhibit GBM in vitro and in vivo.